Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Takeda’s possible US$50bn Shire bid thrown into doubt as UK pharma sells off oncology unit for US$2.4bn

Takeda is reportedly preparing to launch a bid for Shire before the April 25 deadline, but Shire’s oncology unit was one of the key reasons it wanted the takeover in the first place
cancer cells
Without its oncology unit, it remains to be seen whether Takeda is still interested in Shire

Shire PLC (LON:SHP) has agreed to sell off its oncology division to French pharma group Servier for US$2.4bn, raising doubts over the likelihood of a bid from Japanese drugmaker Takeda.

Takeda, which is Japan’s largest drugmaker by sales, first revealed its interest in Shire at the end of March and is said to be weighing up a US$50bn bid for the UK group.

Is Takeda still interested?

At the end of last week, a report from Reuters citing two sources with direct knowledge of the matter claimed Takeda has even gone so far as sounding out potential lenders to help fund the deal.

But Monday’s news that Shire has sold off its cancer treatment unit – which includes its ONCASPAR (leukaemia) and ONIVYDE (pancreas) treatments – has thrown that possible takeover into doubt.

Takeda had identified oncology, along with gastroenterology and neuroscience, as one of the key therapeutic areas which would benefit from the acquisition.

Under UK takeover rules, the Japanese firm has until April 25 to announce whether or not it will make a bid for Shire.

As for Monday’s sale, Shire said the oncology unit – which brought in US$262mln in revenue last year – was no longer part of its future plans.

Proceeds possibly returned to shareholders

“This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio,” said Shire chief executive Flemming Ornskov.

“While the oncology business has delivered high growth and profitability, we have concluded that it is not core to Shire's longer-term strategy.”

Ornskov added that the company would consider returning the proceeds to shareholders through a share-buyback “after the current offer period regarding Takeda's possible offer concludes”.

In late morning trading, Shire shares were up 1.3% at 3,653.5p.

In a note to clients, analysts at Liberum Capital commented: “Strategically this is not a big move given the small size and is not entirely unexpected given Shire is clearly sub-scale in oncology.

“We view the implications for the ongoing Takeda situation as limited given we don’t think oncology was the key element in Takeda’s interest.”

Liberum repeated a ‘hold’ rating and 4,000p price on Shire’s shares.

 -- Updates share price, adds broker comment --

View full SHP profile View Profile

Shire Plc Timeline

Related Articles

June 20 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use